FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158558263> ?p ?o ?g. }

• W2158558263 endingPage "809" @default.
• W2158558263 startingPage "800" @default.
• W2158558263 abstract "Seven drugs are licensed for the treatment of chronic hepatitis B (CHB) in the United Kingdom. Which initial treatment, secondary therapy, and whether antivirals should be given alone or in combination are questions of considerable uncertainty.The aim of this model was to undertake a comprehensive economic evaluation of all antiviral treatments for CHB to recommend the most cost-effective therapeutic sequence.We developed a probabilistic Markov model to compare the cost-effectiveness of all clinically relevant antiviral treatment sequences for nucleos(t)ide-naive adults with hepatitis B e-antigen (HBeAg)-positive or HBeAg-negative CHB. Relative rates of HBeAg seroconversion and viral suppression were obtained from a network meta-analysis. Data on mortality, antiviral drug resistance, durability of response, adverse events, and costs were obtained from published literature. Results are reported in terms of lifetime costs, quality-adjusted life-years (QALYs), and expected net benefit.In the base-case analysis, pegylated interferon alpha-2a (peg-IFN α-2a) followed by tenofovir disoproxil fumarate was most effective and cost-effective in HBeAg-positive patients, with a cost of £7488 per QALY gained compared with no treatment. In HBeAg-negative patients, peg-IFN α-2a followed by entecavir was most effective and cost-effective, with a cost of £6981 per QALY gained. The model was robust to a wide range of sensitivity analyses.Peg-IFN α-2a followed by tenofovir disoproxil fumarate or entecavir is the most effective antiviral treatment strategy for people with both variants of CHB. At a cost of less than £10,000 per QALY gained, these sequences are considered cost-effective in England and Wales. The results of this analysis were used to inform 2013 National Institute for Health and Care Excellence guideline recommendations." @default.
• W2158558263 created "2016-06-24" @default.
• W2158558263 creator A5001794200 @default.
• W2158558263 creator A5009203630 @default.
• W2158558263 creator A5015295914 @default.
• W2158558263 creator A5016986028 @default.
• W2158558263 creator A5045033407 @default.
• W2158558263 creator A5048001382 @default.
• W2158558263 creator A5070099420 @default.
• W2158558263 creator A5085700120 @default.
• W2158558263 creator A5090705887 @default.
• W2158558263 date "2015-09-01" @default.
• W2158558263 modified "2023-10-16" @default.
• W2158558263 title "Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom" @default.
• W2158558263 cites W1526839166 @default.
• W2158558263 cites W1967751247 @default.
• W2158558263 cites W1971303441 @default.
• W2158558263 cites W1976104517 @default.
• W2158558263 cites W1982812988 @default.
• W2158558263 cites W1991094067 @default.
• W2158558263 cites W1999664635 @default.
• W2158558263 cites W2008517556 @default.
• W2158558263 cites W2009509017 @default.
• W2158558263 cites W2012090731 @default.
• W2158558263 cites W2014837723 @default.
• W2158558263 cites W2017172077 @default.
• W2158558263 cites W2017537010 @default.
• W2158558263 cites W2018479084 @default.
• W2158558263 cites W2022625249 @default.
• W2158558263 cites W2022770725 @default.
• W2158558263 cites W2024593231 @default.
• W2158558263 cites W2025530770 @default.
• W2158558263 cites W2048759891 @default.
• W2158558263 cites W2048841284 @default.
• W2158558263 cites W2055002900 @default.
• W2158558263 cites W2059560167 @default.
• W2158558263 cites W2073029663 @default.
• W2158558263 cites W2073466847 @default.
• W2158558263 cites W2080705326 @default.
• W2158558263 cites W2084720260 @default.
• W2158558263 cites W2089571778 @default.
• W2158558263 cites W2089727509 @default.
• W2158558263 cites W2098472552 @default.
• W2158558263 cites W2108147025 @default.
• W2158558263 cites W2115123213 @default.
• W2158558263 cites W2122087900 @default.
• W2158558263 cites W2133291642 @default.
• W2158558263 cites W2137544368 @default.
• W2158558263 cites W2142557452 @default.
• W2158558263 cites W2152532978 @default.
• W2158558263 cites W2156015715 @default.
• W2158558263 cites W2158820949 @default.
• W2158558263 cites W2160654288 @default.
• W2158558263 cites W2162968224 @default.
• W2158558263 cites W2415371986 @default.
• W2158558263 cites W3030265267 @default.
• W2158558263 cites W4241710806 @default.
• W2158558263 doi "https://doi.org/10.1016/j.jval.2015.05.007" @default.
• W2158558263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26409607" @default.
• W2158558263 hasPublicationYear "2015" @default.
• W2158558263 type Work @default.
• W2158558263 sameAs 2158558263 @default.
• W2158558263 citedByCount "17" @default.
• W2158558263 countsByYear W21585582632015 @default.
• W2158558263 countsByYear W21585582632016 @default.
• W2158558263 countsByYear W21585582632017 @default.
• W2158558263 countsByYear W21585582632018 @default.
• W2158558263 countsByYear W21585582632019 @default.
• W2158558263 countsByYear W21585582632023 @default.
• W2158558263 crossrefType "journal-article" @default.
• W2158558263 hasAuthorship W2158558263A5001794200 @default.
• W2158558263 hasAuthorship W2158558263A5009203630 @default.
• W2158558263 hasAuthorship W2158558263A5015295914 @default.
• W2158558263 hasAuthorship W2158558263A5016986028 @default.
• W2158558263 hasAuthorship W2158558263A5045033407 @default.
• W2158558263 hasAuthorship W2158558263A5048001382 @default.
• W2158558263 hasAuthorship W2158558263A5070099420 @default.
• W2158558263 hasAuthorship W2158558263A5085700120 @default.
• W2158558263 hasAuthorship W2158558263A5090705887 @default.
• W2158558263 hasBestOaLocation W21585582631 @default.
• W2158558263 hasConcept C126322002 @default.
• W2158558263 hasConcept C159047783 @default.
• W2158558263 hasConcept C203014093 @default.
• W2158558263 hasConcept C2522874641 @default.
• W2158558263 hasConcept C2775940106 @default.
• W2158558263 hasConcept C2776175608 @default.
• W2158558263 hasConcept C2776461080 @default.
• W2158558263 hasConcept C2777382497 @default.
• W2158558263 hasConcept C2777410769 @default.
• W2158558263 hasConcept C2777869810 @default.
• W2158558263 hasConcept C2780040827 @default.
• W2158558263 hasConcept C2780593183 @default.
• W2158558263 hasConcept C3020491458 @default.
• W2158558263 hasConcept C3020505244 @default.
• W2158558263 hasConcept C71924100 @default.
• W2158558263 hasConceptScore W2158558263C126322002 @default.
• W2158558263 hasConceptScore W2158558263C159047783 @default.
• W2158558263 hasConceptScore W2158558263C203014093 @default.

• next